Multiple Myeloma

Patient Profile 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Switching their focus to the relapsed/refractory setting, experts from the Moffit Cancer Center consider second-line treatment options for patients with multiple myeloma.

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

The Role of Teclistamab in Multiple Myeloma

Expert perspectives on a patient profile of transplant-ineligible multiple myeloma, with considerations for treatment selection and defining transplant ineligibility.

Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation

Dr Ajai Chari explains the mechanism of action of BCMA-targeting bispecifics and the role of teclistamab in multiple myeloma treatment.

Induction Therapy in Transplant-Ineligible NDMM

Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Role of Transplant and Induction Therapies in NDMM

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Selecting Treatment Regimens for Multiple Myeloma at First Relapse

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Choosing the Right Treatment for Patients With Transplant Ineligible MM

Turning to the last module, expert panelists discuss the treatment armamentarium for patients experiencing early relapse in multiple myeloma.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Optimal Selection of Therapy for Patients With Transplant-Eligible NDMM

Patient and disease factors that help to select best first-line therapy in the setting of transplant-ineligible multiple myeloma.

Beth Faiman, PhD, MSN, APN-BC;Sandra Mazzoni, MD;Jack Khouri, MD;Louis Williams, MD

February 3rd 2023

A focused discussion on navigating the treatment armamentarium for patients with transplant-eligible newly diagnosed multiple myeloma.

Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

Beth Faiman, PhD, MSN, APN-BC;Sandra Mazzoni, MD;Jack Khouri, MD;Louis Williams, MD

February 3rd 2023

Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider optimal workup and management strategies.

Clinical Pearls and Unmet Needs in R/R Multiple Myeloma

Joshua Richter, MD

February 3rd 2023

Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.

The Genetics of Multiple Myeloma: Expert Perspectives

ONCOLOGY Staff

February 2nd 2023

Experts discuss the genetics of multiple myeloma, the prevalent testing paradigms in this space, and possibilities for the future.

Treatment Duration in Patients With Transplant-Ineligible NDMM

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

Transplant-Ineligible NDMM: Optimizing Therapy for Frailer Patients

Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

Resources for Patient Education

Experts from the Moffit Cancer Center work to identify frail patients with transplant-ineligible NDMM and consider how best to select first-line therapy for this population.

A Patient’s Experience With a Multiple Myeloma Diagnosis

Nurse Practitioner Kiah Purcell and Registered Nurse Annel Urena explain their role in the diagnosis and education of a patient with multiple myeloma.

DETERMINATION, GRIFFIN, and MASTER Studies

Ajai Chari, MD, provides a quick overview of multiple myeloma and patient Anne-Marie Jacob shares the story of her diagnosis.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Induction Regimen Options in Transplant-Eligible NDMM

Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Approaching Induction Therapy for Patients With Transplant-Ineligible MM

Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Selecting The Appropriate Treatment in Transplant-Eligible Newly Diagnosed MM

Switching their focus to transplant-ineligible multiple myeloma, panelists review available triplet therapy regimens for induction therapy.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD